Compare · AXGN vs DRAD
AXGN vs DRAD
Side-by-side comparison of Axogen Inc. (AXGN) and Digirad Corporation (DRAD): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AXGN and DRAD operate in Biotechnology: Electromedical & Electrotherapeutic Apparatus (Health Care), so they compete in similar markets.
- AXGN carries a market cap of $2.68B.
- AXGN has hit the wire 4 times in the past 4 weeks while DRAD has been quiet.
- AXGN has more recent analyst coverage (8 ratings vs 0 for DRAD).
- Company
- Axogen Inc.
- Digirad Corporation
- Price
- -
- -
- Market cap
- $2.68B
- -
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2004
- News (4w)
- 4
- 0
- Recent ratings
- 8
- 0
Axogen Inc.
AxoGen, Inc., together with its subsidiaries, develops and markets surgical solutions for physical damage or transection to peripheral nerves. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments. Its products also comprise Axoguard Nerve Cap, a porcine submucosa ECM product that is used to protect a peripheral nerve end, as well as separates the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma; and Avive Soft Tissue Membrane, a processed human umbilical cord membrane that can be used as a resorbable soft tissue covering to separate tissues in the surgical bed. In addition, the company offers AxoTouch two point discriminator, a tool that is used for measuring the innervation density of surface area of the skin. It provides its products to hospitals, surgery centers, and military hospitals plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and various oral and maxillofacial surgeons in the United States, Canada, Germany, the United Kingdom and other European countries, South Korea, and internationally. AxoGen, Inc. is headquartered in Alachua, Florida.
Latest AXGN
- EVP & General Counsel Began Marc A exercised 67,500 shares at a strike of $8.16 and sold $3,195,788 worth of shares (67,500 units at $47.34) as part of a pre-agreed trading plan (SEC Form 4)
- Director Wendell Amy Mcbride exercised 13,353 shares at a strike of $14.85 and sold $646,592 worth of shares (13,353 units at $48.42) as part of a pre-agreed trading plan (SEC Form 4)
- Director Weiler Kathy Johnson sold $640,967 worth of shares (14,150 units at $45.30) as part of a pre-agreed trading plan, closing all direct ownership in the company (SEC Form 4)
- Cosmetic Surgery's Next Debate: Rebuild Tissue, Not Fill It
- SEC Form 10-Q filed by Axogen Inc.
- Axogen Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
- Trace Biosciences Announces Strategic Investment from Axogen to Advance Clinical Development of its Nerve Trace Nerve-Specific Imaging Technology
- Axogen, Inc. Reports Second Quarter 2026 Financial Results
- Neuronetics Appoints Nir Naor Chief Financial Officer; Announces Additional Management Changes
- Axogen, Inc. to Report Second Quarter 2026 Financial Results on July 29, 2026
Latest DRAD
- SEC Form 8 filed
- Digirad Corporation to Present at Investor Conferences in November
- Digirad Corporation Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2020
- Digirad Corporation to Release Third Quarter 2020 Financial Results on November 13
- Digirad Corporation to Sell DMS Health for $18.75 Million